MX2007005679A - Metodo para tratamiento de desordenes de movimiento. - Google Patents
Metodo para tratamiento de desordenes de movimiento.Info
- Publication number
- MX2007005679A MX2007005679A MX2007005679A MX2007005679A MX2007005679A MX 2007005679 A MX2007005679 A MX 2007005679A MX 2007005679 A MX2007005679 A MX 2007005679A MX 2007005679 A MX2007005679 A MX 2007005679A MX 2007005679 A MX2007005679 A MX 2007005679A
- Authority
- MX
- Mexico
- Prior art keywords
- myoclonus
- directed
- compound
- formula
- movement disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La invencion esta dirigida a metodos para el tratamiento de desordenes de movimiento mediante el administrar una cantidad efectiva del compuesto de la formula (I) a los pacientes en necesidad del mismo. Mas particularmente, la invencion esta dirigida a un metodo para tratar mioclono incluyendo administrar a un paciente un compuesto de la formula (I) en donde el mioclono no es un mioclono esencial que responde al alcohol con distonia. En algunas incorporaciones, el mioclono es mioclono postipoxica. La invencion tambien esta dirigida a un metodo para tratar distonia, el temblor esencial, el temblor del cerebelo, un movimiento nervioso, corea, incluido administrar a un paciente un compuesto de la formula I.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62664504P | 2004-11-10 | 2004-11-10 | |
PCT/US2005/040877 WO2006053186A2 (en) | 2004-11-10 | 2005-11-09 | Method for treatment of movement disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2007005679A true MX2007005679A (es) | 2007-07-11 |
Family
ID=36337239
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2007005679A MX2007005679A (es) | 2004-11-10 | 2005-11-09 | Metodo para tratamiento de desordenes de movimiento. |
Country Status (10)
Country | Link |
---|---|
US (1) | US20090137565A1 (es) |
EP (1) | EP1809286A4 (es) |
JP (1) | JP2008519847A (es) |
KR (1) | KR20070085838A (es) |
CN (1) | CN101098701A (es) |
AU (1) | AU2005304352A1 (es) |
CA (1) | CA2586975A1 (es) |
IL (1) | IL182906A0 (es) |
MX (1) | MX2007005679A (es) |
WO (1) | WO2006053186A2 (es) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060159743A1 (en) * | 2001-10-25 | 2006-07-20 | Depomed, Inc. | Methods of treating non-nociceptive pain states with gastric retentive gabapentin |
TWI312285B (en) | 2001-10-25 | 2009-07-21 | Depomed Inc | Methods of treatment using a gastric retained gabapentin dosage |
US7612112B2 (en) | 2001-10-25 | 2009-11-03 | Depomed, Inc. | Methods of treatment using a gastric retained gabapentin dosage |
US8702629B2 (en) * | 2005-03-17 | 2014-04-22 | Great Lakes Neuro Technologies Inc. | Movement disorder recovery system and method for continuous monitoring |
US20090176882A1 (en) | 2008-12-09 | 2009-07-09 | Depomed, Inc. | Gastric retentive gabapentin dosage forms and methods for using same |
US8778398B2 (en) | 2008-11-04 | 2014-07-15 | Jazz Pharmaceuticals, Inc. | Immediate release formulations and dosage forms of gamma-hydroxybutyrate |
US8771735B2 (en) | 2008-11-04 | 2014-07-08 | Jazz Pharmaceuticals, Inc. | Immediate release dosage forms of sodium oxybate |
CN101919811A (zh) * | 2009-06-09 | 2010-12-22 | 北京博时安泰液体制剂科技有限公司 | 一种左乙拉西坦注射液及其制备方法 |
CA2794171C (en) | 2010-03-24 | 2018-07-03 | Jazz Pharmaceuticals, Inc. | Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances |
US9050302B2 (en) | 2013-03-01 | 2015-06-09 | Jazz Pharmaceuticals Ireland Limited | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
US10398662B1 (en) | 2015-02-18 | 2019-09-03 | Jazz Pharma Ireland Limited | GHB formulation and method for its manufacture |
AU2016328150B2 (en) | 2015-09-23 | 2020-10-01 | Xw Laboratories Inc. | Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof |
FR3049463B1 (fr) * | 2016-04-01 | 2019-07-05 | Debregeas Et Associes Pharma | Doses unitaires a liberation immediate de ghb ou de l'un de ses sels therapeutiquement acceptables administrees par voie orale et leur utilisation pour maintenir l'abstinence alcoolique |
UY37341A (es) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11000498B2 (en) | 2016-07-22 | 2021-05-11 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US20180263936A1 (en) | 2017-03-17 | 2018-09-20 | Jazz Pharmaceuticals Ireland Limited | Gamma-hydroxybutyrate compositions and their use for the treatment of disorders |
JP7490561B2 (ja) * | 2018-03-22 | 2024-05-27 | リサーチ ファウンデイション オブ ザ シティー ユニヴァーシティ オブ ニューヨーク | 痙縮および関連障害のための治療戦略としてのニューロンのnkcc1の調節 |
JP7472116B2 (ja) | 2018-11-19 | 2024-04-22 | ジャズ ファーマシューティカルズ アイルランド リミテッド | 耐アルコール性製剤 |
CN113473980A (zh) | 2019-03-01 | 2021-10-01 | 弗拉梅尔爱尔兰有限公司 | 在进食状态下具有改善的药代动力学的γ-羟基丁酸酯组合物 |
WO2021067457A1 (en) * | 2019-09-30 | 2021-04-08 | Massachusetts Eye And Ear Infirmary | Objective evaluation of neurological movement disorders from medical imaging |
US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4051842A (en) * | 1975-09-15 | 1977-10-04 | International Medical Corporation | Electrode and interfacing pad for electrical physiological systems |
DE2626348C3 (de) * | 1976-06-11 | 1980-01-31 | Siemens Ag, 1000 Berlin Und 8000 Muenchen | Implantierbare Dosiereinrichtung |
US4383529A (en) * | 1980-11-03 | 1983-05-17 | Wescor, Inc. | Iontophoretic electrode device, method and gel insert |
JPS60168044A (ja) * | 1984-02-10 | 1985-08-31 | Sharp Corp | 感湿素子 |
IL72684A (en) * | 1984-08-14 | 1989-02-28 | Israel State | Pharmaceutical compositions for controlled transdermal delivery of cholinergic or anticholinergic basic drugs |
US4668506A (en) * | 1985-08-16 | 1987-05-26 | Bausch & Lomb Incorporated | Sustained-release formulation containing and amino acid polymer |
US4931279A (en) * | 1985-08-16 | 1990-06-05 | Bausch & Lomb Incorporated | Sustained release formulation containing an ion-exchange resin |
US4713244A (en) * | 1985-08-16 | 1987-12-15 | Bausch & Lomb Incorporated | Sustained-release formulation containing an amino acid polymer with a lower alkyl (C1 -C4) polar solvent |
US4738985A (en) * | 1986-03-19 | 1988-04-19 | The University Of Toronto Innovations Foundations | Pharmaceutical composition and treatment |
US5145682A (en) * | 1986-05-30 | 1992-09-08 | Rutgers, The State University Of New Jersey | Transdermal absorption dosage unit for postmenopausal syndrome treatment and process for administration |
US5990162A (en) * | 1997-08-29 | 1999-11-23 | Orphan Medical, Inc. | Method for treatment of fibromyalgia and chronic fatigue syndrome |
AU779354B2 (en) * | 1998-12-23 | 2005-01-20 | Orphan Medical, Inc. | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
CA2423358C (en) * | 2000-09-22 | 2011-05-17 | Orphan Medical, Inc. | Gamma-hydroxybutyrate compositions containing carbohydrate, lipid or amino acid carriers |
US8193211B2 (en) * | 2004-09-30 | 2012-06-05 | Supernus Pharmaceuticals, Inc. | Controlled release compositions of gamma-hydroxybutyrate |
-
2005
- 2005-11-09 CN CNA2005800424239A patent/CN101098701A/zh active Pending
- 2005-11-09 CA CA002586975A patent/CA2586975A1/en not_active Abandoned
- 2005-11-09 KR KR1020077012803A patent/KR20070085838A/ko not_active Application Discontinuation
- 2005-11-09 US US11/667,530 patent/US20090137565A1/en not_active Abandoned
- 2005-11-09 EP EP05847768A patent/EP1809286A4/en not_active Withdrawn
- 2005-11-09 AU AU2005304352A patent/AU2005304352A1/en not_active Abandoned
- 2005-11-09 WO PCT/US2005/040877 patent/WO2006053186A2/en active Application Filing
- 2005-11-09 JP JP2007541338A patent/JP2008519847A/ja active Pending
- 2005-11-09 MX MX2007005679A patent/MX2007005679A/es not_active Application Discontinuation
-
2007
- 2007-05-01 IL IL182906A patent/IL182906A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP1809286A2 (en) | 2007-07-25 |
WO2006053186A3 (en) | 2006-08-10 |
AU2005304352A1 (en) | 2006-05-18 |
JP2008519847A (ja) | 2008-06-12 |
IL182906A0 (en) | 2007-09-20 |
CA2586975A1 (en) | 2006-05-18 |
WO2006053186A2 (en) | 2006-05-18 |
CN101098701A (zh) | 2008-01-02 |
US20090137565A1 (en) | 2009-05-28 |
KR20070085838A (ko) | 2007-08-27 |
EP1809286A4 (en) | 2010-09-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2007005679A (es) | Metodo para tratamiento de desordenes de movimiento. | |
MX2009002920A (es) | Tratamiento del dolor, diabetes y trastornos del metabolismo de los lipidos. | |
TW200735862A (en) | Prostaglandin reductase inhibitors | |
ZA200810113B (en) | Method for the treatment and prevention of ocular disorders | |
AU5584901A (en) | Use of cyclic gmp-specific phosphodiesterase inhibitors for treatment of parkinson's disease | |
WO2009026176A3 (en) | Antiinfective flavononol compounds and methods of use thereof | |
TW200722087A (en) | Treatment of dermatological diseases and pruritus | |
HRP20080175T3 (en) | Substituted 2-aminotetralines for the preventive treatment of parkinson's disease | |
WO2006081431A3 (en) | Compounds for treating inflammatory and demyelinating diseases | |
MXPA04009784A (es) | Tiazolidin-4-carbonitrilos y analogos y su uso como inhibidores de dipeptidil-peptidas. | |
NO20054476D0 (no) | Forbindelser for behandling av smerte | |
WO2006093348A3 (en) | Method and composition for treating peripheral vascular diseases | |
EP1627635A3 (en) | Benzothiazolium compounds for use in methods of inhibiting NO production and TNF alpha and treating coronaviral infection | |
UA85707C2 (ru) | Бензоксазины для лечения заболеваний дыхательных путей | |
HK1114876A1 (en) | Arthrospira-based compositions and uses thereof | |
ATE356621T1 (de) | (s)-2-n-propylamino-5-hydroxytetralin als d3- agonistisches therapeutikum | |
NO20083036L (no) | Anvendelse av benzofuserte heterocykliske sulfamidderivater for behandling av depresjon | |
MX2009002922A (es) | Derivados de azetidina y azetidona utiles en el tratamiento del dolor y de trastornos del metabolismo lipidico. | |
WO2004110380A3 (en) | Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents | |
UA107562C2 (uk) | Спосіб лікування псоріазу | |
HK1079526A1 (en) | A novel pyrazine compound and its use in the manufacture of a medicament for treating diseases related to serotonin | |
MX2009005351A (es) | Compuestos utiles para tratar trastornos neurodegenerativos. | |
TW200600084A (en) | Anti-coronavirus compounds | |
WO2004096237A3 (en) | Phosphonate analogs for treating metabolic diseases | |
WO2008023003A8 (de) | Arzneimittelkombinationen zur behandlung von atemwegserkrankungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |